NCT06767891View on ClinicalTrials.gov

Real-world Study of Acalabrutinib

Enrolling by invitationOBSERVATIONAL

Enrollment

200

Participants

Timeline

Start Date

July 2, 2024

Primary Completion Date

July 30, 2026

Study Completion Date

January 30, 2028

Conditions

MCLCLL

Trial Locations (1)

200025

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Ruijin Hospital

OTHER